All News

Genentech says Tanox acquisition does not signal a shift in strategy.

Industry points to new reports on Part D to blunt new Congressional critics.

Advertise in the PharmExec Direct Marketing Edition

Advertise in PharmExec Direct

Need to know the latest on new campaigns, agency-client relationships, and personnel changes? Sign up now to receive the latest drug marketing news, including account wins, case studies, and trends on alternate Wednesdays.

Abbott's acquisition of Kos creates a viable contender in the fight for cardiovascular market share.

Judge defines term ahead of Medicare fraud trial.

November 2006 CE.

June 06 BPA Statement

DOMINO SPONSORS MAJOR SUMMIT ON ROLE OF CODING, RFID AND EPC IN SECURE HEALTHCARE SUPPLY CHAINS

Merck's Januvia has a head start, but Novartis isn't sitting idle.

Emerging countries are expected to drive pharma's earnings next year.

After winning a bidding war for Pliva, the well-positioned generic maker is giving pharma reason to worry.

An executive interview with Lee Babiss PhD, VP, Preclinical R & D of Hoffmann-La Roche, Inc, conducted by Patrick Clinton, Editor in Chief of Pharmaceutical Executive. Tune in and hear a real-world perspective on drug repositioning as a new way of filling late-stage pipelines.

Drug giant beefs up early-stage R&D, moving into Genentech's turf.

JAMA study questions effectiveness of popular antidepressants.

After axing oncology, Gilead says it's ready for new therapeutic areas.

October 2006 CE.

Pharmacists have applauded Plan B's behind-the-counter status, and FDA hints that the drug might pave the way for more pharmacy-only OTC products.

The Part D donut hole has arrived, and pharma is scrambling to maintain brand loyalty.

A new, faster recipe for drug development: Chat up regulators. Outsource where you can. And know when to let go.

The recent settlement between branded and generic companies offers a 'win-win' approach to patent challenges.

Company-commissioned report exonerates senior managers, points fingers at sales team

Drug makers used aggressive contracting to retain marketshare after launch of generic simvastatin

Pricing, marketing cases expected to escalate in the future

Pharmaceutical Representative is pleased is pleased to bring you informative, interactive, and cost-effective web seminars. These time-saving events are user friendly and designed to deliver information that will improve your bottom line. Please review the list below for upcoming topics.

It's clear CME is becoming an important part of global healthcare, and there's no better time for pharma companies to capitalize on this growing trend. There's enormous opportunity, but it must be tailored to the distinct clinical environment of each country.

September 2006 CE.